Business Summary: GSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).
Financial Summary: BRIEF: For the three months ended 31 March 2026, GSK plc revenues increased 2% to L7.63B. Net income increased 7% to L1.74B. Revenues reflect Europe segment increase of 19% to L2.08B. Net income benefited from Commercial Operations segment income increase of 6% to L4.15B. Dividend per share increased from L0.16 to L0.17. Basic Earnings per Share excluding Extraordinary Items increased from L0.39726 to L0.43177.